Saturday, 31 October 2026European Markets

MAREL Stock Was 23.89% Up Before The Weekend

Loading stream...

(VIANEWS) - The Market ended the session with MAREL (MAREL.AS) rising 23.89% to €2.80 on Friday, after five sequential sessions in a row of losses. AEX-Index rose 0.44% to €765.66, after two consecutive sessions in a row of gains, on what was a somewhat bullish trend trading session today.

MAREL's last close was €2.26, 46.32% under its 52-week high of €4.21.

About MAREL

Marel hf. develops, distributes, and sells solutions, software, and services to food processing industries in Europe, the Middle East, Africa, the Americas, Asia, and Oceania. The company's Poultry Processing segment offers integrated systems, software, and services for processing broilers, turkeys, and ducks. Its Meat Processing segment supplies primary, secondary, and further processing equipment, systems, software, and services of pork, beef, veal, and sheep. The company's Fish Processing segment offers equipment, systems, software, and services for farmed and wild salmon and whitefish processing. Its Plant, pet and feed segment provides solutions and services to the pet food, plant-based protein, and aqua feed markets. Marel hf. was founded in 1977 and is based in Garðabær, Iceland.

Earnings Per Share

As for profitability, MAREL has a trailing twelve months EPS of €0.05.

PE Ratio

MAREL has a trailing twelve months price to earnings ratio of 56. Meaning, the purchaser of the share is investing €56 for every euro of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 3.87%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

MAREL's EBITDA is 72.92.

Yearly Top and Bottom Value

MAREL's stock is valued at €2.80 at 21:31 EST, way below its 52-week high of €4.21 and way higher than its 52-week low of €2.35.

More news about MAREL (MAREL.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com